{"gene":"BCL2L1","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":1993,"finding":"BCL2L1 encodes two alternatively spliced isoforms: Bcl-xL (anti-apoptotic) and Bcl-xS (pro-apoptotic). Bcl-xL stably transfected into an IL-3-dependent cell line inhibits apoptosis upon growth factor withdrawal at least as well as Bcl-2, while Bcl-xS inhibits the protective effect of Bcl-2.","method":"Stable transfection of IL-3-dependent cell lines; cell survival assays after growth factor withdrawal; molecular cloning and alternative splicing analysis","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — original discovery paper with functional cellular assays, replicated extensively across the field","pmids":["8358789"],"is_preprint":false},{"year":1996,"finding":"Bcl-xL forms stable complexes with Bax both in vitro and in vivo (co-immunoprecipitation), increasing the apoptotic threshold in a dose-dependent manner. Bcl-xS does not form observable heterodimers with other Bcl-2 family members by co-immunoprecipitation from mammalian cells, suggesting it acts by a distinct mechanism rather than by competing for Bax binding.","method":"In vitro binding assays; co-immunoprecipitation from mammalian cells; dose-dependent cell survival assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP and in vitro binding with functional dose-response, replicated across labs","pmids":["8626425"],"is_preprint":false},{"year":1997,"finding":"Bcl-xL inserts into synthetic lipid vesicles or planar lipid bilayers and forms pH-sensitive, cation-selective ion-conducting channels with multiple conductance states, similar to pore-forming bacterial toxins.","method":"Planar lipid bilayer electrophysiology; synthetic lipid vesicle reconstitution; ion channel recordings","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution in lipid bilayers and vesicles, multiple conductance measurements, consistent with structural data","pmids":["9002522"],"is_preprint":false},{"year":1998,"finding":"The loop domain of Bcl-xL is cleaved by caspases in vitro and in cells undergoing apoptosis. Mutation of the caspase cleavage site combined with a BH1 domain mutation impairs death-inhibitory activity. Once cleaved, the C-terminal fragment of Bcl-xL potently induces apoptosis, converting Bcl-xL from protective to lethal.","method":"In vitro caspase cleavage assay; site-directed mutagenesis; cell death assays after Sindbis virus infection or IL-3 withdrawal","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro assay plus mutagenesis plus cellular validation, single lab with multiple orthogonal methods","pmids":["9435230"],"is_preprint":false},{"year":2000,"finding":"Bcr/Abl activates transcription of the BCL-X gene through STAT5. Constitutively active STAT5-1*6 induces Bcl-xL expression and promotes survival. A dominant-negative STAT5 mutant blocks both Bcr/Abl-induced BCL-X promoter activity and Bcl-xL protein increase.","method":"Tetracycline-inducible expression system; BCL-X promoter/luciferase reporter assays; dominant-negative STAT5 expression; Western blotting","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Moderate — promoter reporter assay with dominant-negative epistasis and protein-level confirmation, single lab, two orthogonal methods","pmids":["10979976"],"is_preprint":false},{"year":2007,"finding":"The RNA-binding protein Sam68 binds BCL-x mRNA and modulates its alternative splicing: Sam68 depletion increases anti-apoptotic Bcl-xL, while its overexpression increases pro-apoptotic Bcl-xS. Tyrosine phosphorylation of Sam68 by Fyn kinase inverts this effect, favoring Bcl-xL splice site selection. Sam68 interacts with hnRNP A1, and hnRNP A1 depletion or mutations impairing this interaction attenuate Bcl-xS splicing.","method":"RNA interference; overexpression; co-immunoprecipitation; minigene splicing assays; point mutation analysis of RNA-binding domain","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — RNAi knockdown, overexpression, co-IP, and kinase epistasis, single lab, multiple orthogonal methods","pmids":["17371836"],"is_preprint":false},{"year":2007,"finding":"PKC inhibition (including staurosporine and more specific PKC inhibitors) shifts BCL-x pre-mRNA splicing toward the pro-apoptotic Bcl-xS isoform. This requires active transcription but no new protein synthesis and is independent of caspase activation. An exonic region upstream of the Bcl-xS 5' splice site mediates the staurosporine-dependent splicing shift when transplanted into other alternative splicing units.","method":"PKC inhibitor treatment; minigene splicing assays with deletion and transplant constructs; actinomycin D and caspase inhibitor controls; RT-PCR isoform analysis","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — minigene dissection of cis element plus pharmacological epistasis, single lab","pmids":["17923691"],"is_preprint":false},{"year":2008,"finding":"Bcl-xL inhibits mitochondrial outer membrane permeabilization (MOMP) by competing with Bax for activation by tBid. Using full-length recombinant proteins and liposome/mitochondria permeabilization assays, tBid recruits both Bcl-xL and Bax to membranes. Mutagenesis shows both Bcl-xL–tBid and Bcl-xL–Bax interactions contribute to anti-apoptotic function. Bcl-xL sequesters tBid and Bax in nonproductive interactions without forming oligomers, functioning as a dominant-negative Bax.","method":"In vitro liposome permeabilization assay; isolated mitochondria MOMP assay; full-length recombinant protein reconstitution; site-directed mutagenesis abolishing specific interactions","journal":"PLoS biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution with recombinant proteins, mutagenesis of individual interactions, multiple substrates tested","pmids":["18547146"],"is_preprint":false},{"year":2009,"finding":"Membrane strongly promotes binding between tBid and Bcl-xL (truncated at C-terminus). Only the active form tBid (not full-length BID) binds Bcl-xL. A BH3 peptide from BID disrupts the tBid-Bcl-xL complex in solution but only partially in lipid bilayers, indicating that tBid–Bcl-xL interactions in membrane are distinct from those in solution.","method":"Fluorescence correlation spectroscopy (FCS) in solution and in lipid bilayers; BH3 peptide competition assay","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — quantitative biophysical reconstitution in defined membrane environments with competition assay, single lab, rigorous controls","pmids":["19820711"],"is_preprint":false},{"year":2009,"finding":"Bcl-xL increases the rates of both mitochondrial fission and fusion in neurons, and importantly increases mitochondrial biomass, resulting in longer organelle morphology. These effects are measured in neuronal processes using fluorescence microscopy and computational analysis.","method":"Fluorescence microscopy with computational fission/fusion frequency measurement; overexpression of Bcl-xL in cultured neurons","journal":"The Journal of cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct quantitative live-imaging with computational analysis, overexpression with defined phenotypic readout, single lab","pmids":["19255249"],"is_preprint":false},{"year":2011,"finding":"Bcl-xL retrotranslocates Bax from the mitochondria back into the cytosol in healthy cells. FLIP (fluorescence loss in photobleaching) reveals constant retrotranslocation of wild-type Bax but not intramolecular disulfide-tethered Bax (which is locked in its cytosolic conformation and accumulates on mitochondria). Bcl-xL retrotranslocation activity depends on pro-survival Bcl-2 family proteins.","method":"Intramolecular disulfide tethering to constrain Bax conformation; fluorescence loss in photobleaching (FLIP); cell-free MOMP assay; detergent co-immunoprecipitation","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — FLIP live-cell imaging with conformational tethering mutants, cell-free MOMP, and co-IP, rigorous mechanistic dissection","pmids":["21458670"],"is_preprint":false},{"year":2014,"finding":"BCL2L1/Bcl-xL (but not BCL2) suppresses FUNDC1-mediated mitophagy under hypoxia through its BH3 domain. Mechanistically, Bcl-xL interacts with and inhibits the mitochondrial phosphatase PGAM5, preventing dephosphorylation of FUNDC1 at Ser13, which is required for mitophagy activation.","method":"Co-immunoprecipitation of Bcl-xL and PGAM5; phosphorylation assays of FUNDC1 Ser13; BCL2 vs BCL2L1 comparison; BH3 domain requirement; mitophagy quantification","journal":"Autophagy","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP, phosphorylation state analysis, domain mapping, BCL2 isoform specificity control, single lab with multiple orthogonal methods","pmids":["25126723"],"is_preprint":false},{"year":2014,"finding":"Mst1 phosphorylates Bcl-xL at Ser14 within the BH4 domain, antagonizing Bcl-xL–Bax binding. This activates Bax and triggers mitochondria-mediated apoptosis in cardiac myocytes. Mst1 activation is localized to mitochondria via a K-Ras–RASSF1A–Mst1 signaling cassette in response to oxidative stress.","method":"In vitro kinase assay; site-directed mutagenesis of Ser14; co-immunoprecipitation of Bcl-xL and Bax; mitochondrial fractionation; cardiac myocyte apoptosis assays","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with mutagenesis, co-IP, subcellular fractionation, and cellular apoptosis readout, single lab, multiple orthogonal methods","pmids":["24813943"],"is_preprint":false},{"year":2015,"finding":"Bcl-xL physically interacts with ceramide via the hydrophobic groove, and this interaction inhibits ceramide channel formation in mitochondrial outer membranes. Bcl-xL point mutations that specifically weaken ceramide binding reduce the ability of Bcl-xL to inhibit ceramide channel formation and protect cells from apoptosis in a stimulus-dependent manner, distinct from but overlapping with Bax channel regulation.","method":"Site-directed mutagenesis of Bcl-xL hydrophobic groove; planar lipid membrane ceramide channel assay; fluorescently-labeled ceramide binding; stable expression of mutants in Bcl-xL-deficient cells; apoptosis assays","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 / Moderate — mutagenesis, in vitro channel reconstitution, and in vivo functional rescue, single lab, multiple orthogonal methods","pmids":["26215742"],"is_preprint":false},{"year":2015,"finding":"Bcl-xL conformation upon membrane integration: the C-terminus interacts with a conserved surface groove in the water-soluble state and inserts across the phospholipid bilayer in the membrane-bound state. Contrary to current models, membrane binding does not induce a conformational change in the soluble domain; both states bind a known ligand with affinities modulated by the protein state.","method":"NMR spectroscopy of full-length Bcl-xL in detergent-free environments; lipid bilayer reconstitution; ligand binding affinity measurements","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structural analysis with functional ligand binding validation in both soluble and membrane states, single lab","pmids":["25731750"],"is_preprint":false},{"year":2016,"finding":"Physiological restraint of Bak by Bcl-xL is essential for cell survival in vivo. A Bak mutation (E75L in mouse, Q77L in human) specifically disrupts interaction with Bcl-xL without affecting Bak structure or killing activity. Loss of Bcl-xL binding to Bak causes increased apoptotic sensitivity in vitro and significant defects in T-cell and blood platelet survival in vivo.","method":"Crystal structure of Bak mutant; surface plasmon resonance binding measurements; mouse genetics (Bak knock-in); T-cell and platelet survival assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 / Strong — structure-guided mutagenesis with binding quantification plus in vivo genetic model, multiple orthogonal methods","pmids":["27198225"],"is_preprint":false},{"year":2017,"finding":"BCL-xL directly interacts with constitutively active RAS in a BH4 domain-dependent manner. This interaction favors full activation of RAS downstream signaling, leading to RAS-induced expression of stemness regulators and maintenance of cancer initiating cell phenotype, independent of apoptotic pressure.","method":"Co-immunoprecipitation of BCL-xL and RAS; BH4 domain mutants; comparative proteomics; functional stemness assays","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP and domain mutants plus functional assays, single lab, two orthogonal methods","pmids":["29066722"],"is_preprint":false},{"year":2017,"finding":"PRMT2 interacts with the splicing factor SAM68 via its SH3 domain and regulates SAM68 subcellular localization. PRMT2 expression promotes an increase in the BCL-xL/BCL-xS splicing ratio in TNF-α or LPS-stimulated cells, linking PRMT2 to BCL-x alternative splicing regulation.","method":"Proteomics (SH3 domain pull-down); co-immunoprecipitation of PRMT2 and SAM68; subcellular localization analysis; RT-PCR splicing isoform quantification","journal":"Journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-IP and domain pull-down plus splicing readout, single lab","pmids":["28057797"],"is_preprint":false},{"year":2018,"finding":"RNA G-quadruplexes (G4s) form in BCL-x pre-mRNA near each of the two alternative 5' splice sites. G4-stabilizing ligands (including ellipticine GQC-05) shift BCL-x splicing, antagonizing the major 5' splice site leading to Bcl-xL and activating the alternative splice site leading to pro-apoptotic Bcl-xS. Ligands act independently at the two splice sites.","method":"G4 ligand panel treatment; minigene splicing assays; endogenous splicing RT-PCR; apoptosis assays; structure-activity relationship analysis of G4 ligands","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional ligand panel with structure-activity relationship and minigene validation, single lab","pmids":["29156002"],"is_preprint":false},{"year":2021,"finding":"SRSF1 promotes splicing of the long anti-apoptotic Bcl-xL isoform, which then interacts with Beclin1 to dissociate the Beclin1-PIK3C3 complex, thereby suppressing autophagosome formation. SRSF1 also directly interacts with PIK3C3 to disrupt Beclin1-PIK3C3 interaction.","method":"Splicing assays (RT-PCR); co-immunoprecipitation of Bcl-xL and Beclin1; co-immunoprecipitation of SRSF1 and PIK3C3; LC3-II accumulation assays; siRNA knockdown","journal":"Signal transduction and targeted therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP of protein complexes plus splicing and autophagy functional readouts, single lab","pmids":["33664238"],"is_preprint":false},{"year":2023,"finding":"RBM25 directly and specifically binds to GQ-2, an RNA G-quadruplex in BCL-x pre-mRNA near the alternative 5' splice site leading to Bcl-xS. This RBM25–rG4 interaction requires the RE (arginine-glutamate-rich) motif of RBM25 and is crucial for Bcl-xS production. G4 ligands (PhenDC3, PhenDH8, PhenDH9) enhance RBM25 binding to GQ-2 rG4, promoting Bcl-xS expression and apoptosis.","method":"In vitro RNA pull-down; EMSA; G4 ligand binding assays; RBM25 domain mutagenesis; minigene and endogenous splicing assays; apoptosis assays; G4 ligand screen of 90 compounds","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution of protein-RNA interaction with domain mutagenesis, G4 ligand competition, and functional splicing/apoptosis validation, single lab, multiple orthogonal methods","pmids":["37811881"],"is_preprint":false},{"year":2004,"finding":"FAST (Fas-activated serine/threonine phosphoprotein) localizes to mitochondria and interacts with BCL-xL at the mitochondrial membrane. The BCL-xL binding domain of FAST maps to a BH3-related domain distinct from the mitochondrial-tethering domain (MTD). Both domains are required for FAST–BCL-xL interaction, but the MTD requirement can be satisfied by a heterologous MTD.","method":"Immunofluorescence microscopy; subcellular fractionation; co-immunoprecipitation; domain deletion/transplant experiments","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP with domain mapping and heterologous domain rescue, single lab","pmids":["15110758"],"is_preprint":false},{"year":2003,"finding":"Bcl-xS expressed in Xenopus oocytes localizes predominantly to mitochondria and induces caspase-dependent cytochrome c release that requires the BH3 domain. This apoptotic effect is inhibited by co-expression of Bcl-2 or Bcl-xL. The transmembrane domain and BH3 domain of Bcl-xS are both required for apoptotic effect.","method":"Xenopus oocyte expression system; subcellular fractionation; cytochrome c release assay; caspase inhibitor treatment; BH3 and transmembrane domain mutagenesis","journal":"Molecular cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo oocyte expression with domain mutagenesis and mechanistic inhibitor controls, single lab","pmids":["12556558"],"is_preprint":false},{"year":2008,"finding":"Nucleolin binds specifically to AU-rich elements (AUUUA) in the 3'-UTR of BCL-xL mRNA and stabilizes it. Nucleolin overexpression stabilizes BCL-xL mRNA in cells, while nucleolin siRNA knockdown shortens BCL-xL mRNA half-life. The stabilizing effect depends on the poly(A) tail and involves nucleolin–poly(A)-binding protein interaction via RGG motifs.","method":"RNA affinity capture with synthetic Bcl-xL 3'-UTR; mass spectrometry identification; RIP (RNA immunoprecipitation); siRNA knockdown; mRNA half-life measurements; overexpression","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA affinity capture with MS identification plus functional mRNA stability assays, single lab","pmids":["18281479"],"is_preprint":false},{"year":2019,"finding":"BMPRII deficiency modulates alternative splicing of BCL-x transcripts in a cell-type-specific manner: promoting Bcl-xL in PASMCs while inhibiting it in endothelial cells. This pro-survival effect is mediated through ALK1 but not ALK3. BMPRII physically interacts with ALK1, and pathogenic mutations in BMPR2 abolish this interaction.","method":"Co-immunoprecipitation of BMPRII and ALK1; RT-PCR splicing isoform analysis; cell-type-specific knockdown; apoptosis assays; analysis of PAH patient cells and lungs","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP with pathogenic mutation disruption, splicing analysis in patient-derived cells, single lab","pmids":["30809644"],"is_preprint":false},{"year":2021,"finding":"NOXA upregulation leads to proteasomal degradation of BCL2L1 (Bcl-xL) in daunorubicin-treated AML cells, through the NOX4-ROS-p38 MAPK-GSK3β-CREB signaling axis. Restoration of BCL2L1 expression alleviates daunorubicin-induced mitochondrial depolarization and cell death. NOXA associates with both Bcl-xL and MCL1 by immunoprecipitation.","method":"Immunoprecipitation; proteasome inhibitor rescue experiments; siRNA knockdown of pathway components; Western blotting; mitochondrial membrane potential assays","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP, proteasomal rescue, pathway inhibitor epistasis, single lab","pmids":["33982799"],"is_preprint":false},{"year":2006,"finding":"BCL-xL is required for dendritic cell survival in vivo. Conditional deletion of bcl-x in skin-residing dendritic cells causes rapid apoptotic disappearance from draining lymph nodes and failure to mount effective immune responses. Trans-complementation with BCL-xL rescues DC survival, and RNAi silencing of the Bcl-xL isoform (but not Bcl-xS) specifically recapitulates the survival defect.","method":"Cre-loxP conditional gene deletion in DCs; gene gun DNA vaccine immunization; RNA interference isoform-specific silencing; trans-complementation with Bcl-xL","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional KO with isoform-specific RNAi and complementation rescue, in vivo model with defined cellular phenotype","pmids":["15383573"],"is_preprint":false},{"year":2010,"finding":"Noxa co-immunoprecipitates with endogenous Bcl-xL in neuroblastoma cells (in addition to MCL1), and this association functionally neutralizes Bcl-xL. Retroviral expression of Bcl-xL (but not MCL1) prevents bortezomib-induced apoptosis, and Noxa knockdown reduces cell death, establishing that Noxa-mediated neutralization of Bcl-xL is required for bortezomib-induced apoptosis.","method":"Co-immunoprecipitation; shRNA knockdown; retroviral overexpression; apoptosis assays","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP, shRNA epistasis, and isoform-selective rescue, single lab","pmids":["20051518"],"is_preprint":false},{"year":2015,"finding":"Bcl-xL depletion in hippocampal neurons impairs neurite outgrowth followed by delayed cell death dependent on upregulation of death receptor 6 (DR6). DR6 depletion partially rescues neuronal process loss, placing DR6 downstream of Bcl-xL in the regulation of neuronal outgrowth. Under hypoxia, Bcl-xL-depleted neurons show increased DR6, neuronal process loss, and death.","method":"shRNA depletion of Bcl-xL and DR6; neurite outgrowth measurement; hypoxia model; epistasis by DR6 rescue of Bcl-xL depletion phenotype","journal":"Antioxidants & redox signaling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — knockdown epistasis with defined neuronal phenotype, single lab","pmids":["24787232"],"is_preprint":false}],"current_model":"BCL2L1 produces two antagonistic splice isoforms (Bcl-xL and Bcl-xS) through alternative splicing regulated by multiple RNA-binding proteins (Sam68, RBM25, SRSF1, PRMT2), signaling pathways (PKC, BMPRII-ALK1), and RNA G-quadruplex structures; Bcl-xL, the predominant anti-apoptotic isoform, localizes to mitochondrial, endoplasmic reticulum, and nuclear outer membranes where it inhibits apoptosis by: (1) retrotranslocating Bax from mitochondria to the cytosol, (2) directly binding and restraining Bak via its hydrophobic groove, (3) competing with Bax for membrane recruitment and oligomerization by sequestering tBid and activated Bax, (4) inhibiting ceramide channel formation through its hydrophobic groove, (5) forming a pH-sensitive cation-selective ion channel; Bcl-xL activity is regulated post-translationally by Mst1-mediated phosphorylation at Ser14 (BH4 domain, antagonizing Bax binding) and by caspase cleavage of its loop domain (converting it to a pro-apoptotic fragment); Bcl-xL also suppresses FUNDC1-mediated mitophagy by interacting with and inhibiting PGAM5 phosphatase, promotes autophagy suppression by binding Beclin1 to displace PIK3C3, enhances mitochondrial fission/fusion and biomass in neurons, modulates synaptic plasticity through mitochondrial bioenergetics, and interacts with RAS in a BH4-dependent manner to promote cancer stem cell signaling."},"narrative":{"mechanistic_narrative":"BCL2L1 is a central rheostat of the intrinsic apoptotic pathway whose pre-mRNA is alternatively spliced into the anti-apoptotic Bcl-xL and the pro-apoptotic Bcl-xS isoforms, which functionally oppose one another [PMID:8358789]. Bcl-xL restrains mitochondrial outer membrane permeabilization through several converging mechanisms: it forms stable heterodimers with Bax to raise the apoptotic threshold [PMID:8626425], directly binds and physiologically restrains Bak through interactions essential for T-cell and platelet survival in vivo [PMID:27198225], retrotranslocates Bax from mitochondria back to the cytosol in healthy cells [PMID:21458670], and competes with Bax for membrane recruitment by sequestering tBid and activated Bax in nonproductive complexes without oligomerizing, acting as a dominant-negative Bax [PMID:18547146, PMID:19820711]. Beyond protein–protein restraint, Bcl-xL inserts into membranes to form pH-sensitive, cation-selective ion channels [PMID:9002522] and binds ceramide via its hydrophobic groove to block ceramide channel formation [PMID:26215742]; structural work shows its C-terminus toggles between a surface groove in the soluble state and a transmembrane configuration upon membrane integration [PMID:25731750]. Bcl-xL activity is set post-translationally—Mst1 phosphorylation at Ser14 in the BH4 domain antagonizes Bax binding and licenses apoptosis [PMID:24813943], while caspase cleavage of its loop domain converts Bcl-xL into a pro-apoptotic fragment [PMID:9435230]—and is opposed by the BH3-only protein Noxa, which neutralizes Bcl-xL and targets it for proteasomal degradation [PMID:20051518, PMID:33982799]. The protective Bcl-xL isoform is essential for survival of dendritic cells [PMID:15383573] and supports neuronal outgrowth and survival [PMID:24787232], and it also discharges apoptosis-independent roles: suppressing FUNDC1-mediated mitophagy by inhibiting the PGAM5 phosphatase [PMID:25126723], suppressing autophagy by binding Beclin1 to displace PIK3C3 [PMID:33664238], promoting mitochondrial fission/fusion and biomass in neurons [PMID:19255249], and engaging active RAS through its BH4 domain to sustain cancer stem cell signaling [PMID:29066722]. The Bcl-xL/Bcl-xS ratio is itself heavily regulated at the RNA level: Sam68 (modulated by Fyn phosphorylation and hnRNP A1) [PMID:17371836], PKC signaling acting on a cis exonic element [PMID:17923691], PRMT2 [PMID:28057797], SRSF1 [PMID:33664238], and RNA G-quadruplexes near the competing 5' splice sites—read by RBM25 and tunable by G4 ligands—collectively determine isoform choice [PMID:29156002, PMID:37811881], while transcription is driven by Bcr/Abl–STAT5 [PMID:10979976] and mRNA stability by nucleolin binding the 3'-UTR [PMID:18281479].","teleology":[{"year":1993,"claim":"Established that a single gene encodes two functionally opposing apoptotic regulators, defining BCL2L1 as a splicing-controlled switch rather than a single anti-apoptotic factor.","evidence":"Molecular cloning and stable transfection of IL-3-dependent cells with survival assays after growth factor withdrawal","pmids":["8358789"],"confidence":"High","gaps":["Mechanism by which Bcl-xS antagonizes survival not resolved","Splicing regulators unknown at this stage"]},{"year":1996,"claim":"Showed Bcl-xL acts in part by direct heterodimerization with Bax, providing a biochemical basis for raising the apoptotic threshold.","evidence":"In vitro binding and reciprocal co-IP from mammalian cells with dose-dependent survival assays","pmids":["8626425"],"confidence":"High","gaps":["Whether Bax sequestration is the dominant in vivo mechanism unaddressed","Bcl-xS mechanism remained distinct and undefined"]},{"year":1997,"claim":"Demonstrated Bcl-xL is itself a membrane pore-former, suggesting a channel activity intrinsic to its function beyond protein binding.","evidence":"Planar lipid bilayer electrophysiology and synthetic vesicle reconstitution","pmids":["9002522"],"confidence":"High","gaps":["Physiological substrate/ion of the channel in cells not established","Relationship of channel activity to apoptosis control unclear"]},{"year":1998,"claim":"Revealed that caspase cleavage converts the protective Bcl-xL into a lethal fragment, establishing a feed-forward proteolytic switch during apoptosis.","evidence":"In vitro caspase cleavage, site-directed mutagenesis, and cell death assays","pmids":["9435230"],"confidence":"High","gaps":["In vivo contribution of the cleavage fragment to physiological death unquantified","Structural basis of the pro-apoptotic fragment unknown"]},{"year":2000,"claim":"Identified Bcr/Abl–STAT5 as a transcriptional driver of BCL-X, linking oncogenic signaling to Bcl-xL-mediated survival.","evidence":"Inducible expression, BCL-X promoter/luciferase reporter, and dominant-negative STAT5 epistasis","pmids":["10979976"],"confidence":"High","gaps":["Direct STAT5 binding to the promoter not mapped","Effect on isoform ratio versus total expression not separated"]},{"year":2007,"claim":"Defined RNA-level control of isoform choice via Sam68 and showed kinase signaling (Fyn, PKC) and a cis exonic element steer splicing toward Bcl-xL or Bcl-xS.","evidence":"RNAi, overexpression, co-IP, kinase epistasis, and minigene splicing assays with cis-element transplantation","pmids":["17371836","17923691"],"confidence":"High","gaps":["Direct splice-site mechanism of Sam68/PKC integration unresolved","PKC findings are Medium-confidence single-lab"]},{"year":2008,"claim":"Reconstituted MOMP inhibition with recombinant proteins, establishing that Bcl-xL functions as a dominant-negative Bax by sequestering both tBid and activated Bax without oligomerizing.","evidence":"In vitro liposome and isolated-mitochondria permeabilization with full-length recombinant proteins and interaction-abolishing mutants","pmids":["18547146"],"confidence":"High","gaps":["Relative weighting of tBid versus Bax sequestration in cells not fixed","Membrane context of these interactions only partly captured"]},{"year":2009,"claim":"Showed Bcl-xL has apoptosis-independent effects on mitochondrial dynamics, increasing fission, fusion, and biomass in neurons.","evidence":"Live fluorescence imaging with computational fission/fusion analysis after Bcl-xL overexpression in neurons","pmids":["19255249"],"confidence":"Medium","gaps":["Overexpression-based; loss-of-function effect on dynamics untested here","Molecular effector linking Bcl-xL to fission/fusion machinery unknown"]},{"year":2009,"claim":"Quantified that the membrane environment, not solution conditions, governs tBid–Bcl-xL binding and that only active tBid engages Bcl-xL.","evidence":"Fluorescence correlation spectroscopy in solution and lipid bilayers with BH3 peptide competition","pmids":["19820711"],"confidence":"High","gaps":["Structural basis of the distinct membrane-bound complex unresolved","Generality to other BH3 ligands not tested"]},{"year":2011,"claim":"Established retrotranslocation of Bax from mitochondria to cytosol as a continuous, Bcl-xL-dependent surveillance mechanism in healthy cells.","evidence":"FLIP live-cell imaging with conformation-locking Bax disulfide mutants, cell-free MOMP, and co-IP","pmids":["21458670"],"confidence":"High","gaps":["Energetics and directionality determinants of retrotranslocation incompletely defined","How signaling tips retrotranslocation toward MOMP not resolved"]},{"year":2014,"claim":"Connected post-translational control and non-apoptotic function: Mst1 Ser14 phosphorylation disarms Bcl-xL–Bax restraint, while Bcl-xL inhibits PGAM5 to suppress FUNDC1-mediated mitophagy.","evidence":"In vitro kinase assay, Ser14 mutagenesis, co-IP, fractionation, and mitophagy quantification with BCL2 isoform controls","pmids":["24813943","25126723"],"confidence":"High","gaps":["In vivo significance of Ser14 phosphorylation outside cardiac myocytes unclear","Structural basis of Bcl-xL–PGAM5 inhibition unmapped"]},{"year":2015,"claim":"Expanded Bcl-xL membrane biology: it binds ceramide to block ceramide channels, and structural work defined how its C-terminus repartitions between groove and bilayer without altering the soluble fold.","evidence":"Hydrophobic-groove mutagenesis with planar-membrane ceramide channel assays and NMR of full-length protein in soluble and membrane states","pmids":["26215742","25731750"],"confidence":"High","gaps":["Physiological frequency of ceramide-channel inhibition versus Bax regulation unquantified","Functional state of the membrane-inserted C-terminus in apoptosis control unresolved"]},{"year":2016,"claim":"Demonstrated in vivo that Bcl-xL restraint of Bak (not only Bax) is essential, using a binding-selective Bak mutant that compromises T-cell and platelet survival.","evidence":"Crystal structure of Bak mutant, SPR binding, and Bak knock-in mouse genetics with survival assays","pmids":["27198225"],"confidence":"High","gaps":["Tissue-specific dependence on Bak versus Bax restraint not fully mapped","Interplay with other pro-survival relatives in vivo unaddressed"]},{"year":2017,"claim":"Extended Bcl-xL into oncogenic signaling, showing a BH4-dependent interaction with active RAS that sustains stemness independent of apoptotic pressure, and added PRMT2 as a splicing-ratio regulator.","evidence":"Co-IP with BH4 domain mutants and stemness assays; PRMT2–SAM68 SH3 pull-down with splicing readout","pmids":["29066722","28057797"],"confidence":"Medium","gaps":["RAS interaction shown by co-IP without reciprocal structural validation","Direct versus indirect role of PRMT2 on splice-site selection unresolved"]},{"year":2018,"claim":"Identified RNA G-quadruplexes near both alternative 5' splice sites as druggable structural determinants of Bcl-xL/Bcl-xS choice.","evidence":"G4-ligand panel with minigene and endogenous splicing RT-PCR plus apoptosis assays","pmids":["29156002"],"confidence":"Medium","gaps":["Endogenous proteins reading the G4s not identified in this study","Single-lab functional ligand data"]},{"year":2021,"claim":"Linked SRSF1-driven Bcl-xL production to autophagy suppression via Beclin1–PIK3C3 dissociation, and showed NOXA-driven proteasomal degradation of Bcl-xL during chemotherapy.","evidence":"Splicing RT-PCR with Beclin1/PIK3C3 co-IPs and LC3-II assays; NOXA co-IP with proteasome-inhibitor rescue and pathway epistasis","pmids":["33664238","33982799"],"confidence":"Medium","gaps":["Direct versus splicing-mediated contribution of SRSF1 to autophagy not fully separated","E3 ligase mediating NOXA-driven degradation not identified"]},{"year":2023,"claim":"Identified RBM25 as the direct G-quadruplex reader (via its RE motif) that promotes Bcl-xS production, providing a protein basis for G4-ligand-tunable splicing.","evidence":"In vitro RNA pull-down, EMSA, RBM25 domain mutagenesis, G4-ligand competition, and splicing/apoptosis assays","pmids":["37811881"],"confidence":"High","gaps":["Interplay of RBM25 with other splicing factors at the locus unresolved","Structural model of the RBM25–rG4 complex not determined"]},{"year":null,"claim":"How the many layers of regulation—transcription, mRNA stability, splice-isoform choice, post-translational modification, and degradation—are integrated to set the Bcl-xL/Bcl-xS balance in a given cell context remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified quantitative model linking splicing regulators to apoptotic outcome","Context-specific weighting of apoptotic versus non-apoptotic Bcl-xL functions unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[2]},{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[7,10,1,15]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[11,12]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[13]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[9,11]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,1,7,10,15]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[11,19]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[5,18,20]}],"complexes":[],"partners":["BAX","BAK1","BID","PGAM5","BECN1","PMAIP1","HRAS","SAM68"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q07817","full_name":"Bcl-2-like protein 1","aliases":["Apoptosis regulator Bcl-X"],"length_aa":233,"mass_kda":26.0,"function":"Potent inhibitor of cell death. Inhibits activation of caspases. Appears to regulate cell death by blocking the voltage-dependent anion channel (VDAC) by binding to it and preventing the release of the caspase activator, CYC1, from the mitochondrial membrane. Also acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis Isoform Bcl-X(L) also regulates presynaptic plasticity, including neurotransmitter release and recovery, number of axonal mitochondria as well as size and number of synaptic vesicle clusters. During synaptic stimulation, increases ATP availability from mitochondria through regulation of mitochondrial membrane ATP synthase F(1)F(0) activity and regulates endocytic vesicle retrieval in hippocampal neurons through association with DMN1L and stimulation of its GTPase activity in synaptic vesicles. May attenuate inflammation impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release (PubMed:17418785) Isoform Bcl-X(S) promotes apoptosis","subcellular_location":"Mitochondrion inner membrane; Mitochondrion outer membrane; Mitochondrion matrix; Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane; Cytoplasm, cytosol; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome; Nucleus membrane","url":"https://www.uniprot.org/uniprotkb/Q07817/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/BCL2L1","classification":"Common Essential","n_dependent_lines":1074,"n_total_lines":1208,"dependency_fraction":0.8890728476821192},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BCL2L1","total_profiled":1310},"omim":[{"mim_id":"619936","title":"ANKYRIN REPEAT- AND SOCS BOX-CONTAINING PROTEIN 17; ASB17","url":"https://www.omim.org/entry/619936"},{"mim_id":"617937","title":"RNA-BINDING MOTIF PROTEIN 11; RBM11","url":"https://www.omim.org/entry/617937"},{"mim_id":"616182","title":"CHRONIC MOUNTAIN SICKNESS, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/616182"},{"mim_id":"614939","title":"PHOSPHOGLYCERATE MUTASE FAMILY, MEMBER 5; PGAM5","url":"https://www.omim.org/entry/614939"},{"mim_id":"613558","title":"DEAFNESS, AUTOSOMAL DOMINANT 51; DFNA51","url":"https://www.omim.org/entry/613558"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Mitochondria","reliability":"Approved"},{"location":"Nucleoli fibrillar center","reliability":"Additional"},{"location":"Acrosome","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/BCL2L1"},"hgnc":{"alias_symbol":["BCLX","BCL2L","Bcl-X","bcl-xL","bcl-xS","PPP1R52"],"prev_symbol":[]},"alphafold":{"accession":"Q07817","domains":[{"cath_id":"1.10.437.10","chopping":"2-23_81-229","consensus_level":"high","plddt":81.8612,"start":2,"end":229}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q07817","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q07817-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q07817-F1-predicted_aligned_error_v6.png","plddt_mean":72.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BCL2L1","jax_strain_url":"https://www.jax.org/strain/search?query=BCL2L1"},"sequence":{"accession":"Q07817","fasta_url":"https://rest.uniprot.org/uniprotkb/Q07817.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q07817/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q07817"}},"corpus_meta":[{"pmid":"8358789","id":"PMC_8358789","title":"bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death.","date":"1993","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8358789","citation_count":2985,"is_preprint":false},{"pmid":"9002522","id":"PMC_9002522","title":"Bcl-x(L) forms an ion channel in synthetic lipid membranes.","date":"1997","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9002522","citation_count":687,"is_preprint":false},{"pmid":"21458670","id":"PMC_21458670","title":"Bcl-x(L) retrotranslocates Bax from the mitochondria into the cytosol.","date":"2011","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/21458670","citation_count":506,"is_preprint":false},{"pmid":"9435230","id":"PMC_9435230","title":"Modulation of cell death by Bcl-XL through caspase interaction.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9435230","citation_count":449,"is_preprint":false},{"pmid":"7655019","id":"PMC_7655019","title":"Expression of bcl-xL can confer a multidrug resistance phenotype.","date":"1995","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/7655019","citation_count":371,"is_preprint":false},{"pmid":"17371836","id":"PMC_17371836","title":"The RNA-binding protein Sam68 modulates the alternative splicing of Bcl-x.","date":"2007","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/17371836","citation_count":270,"is_preprint":false},{"pmid":"18547146","id":"PMC_18547146","title":"Bcl-XL inhibits membrane permeabilization by competing with Bax.","date":"2008","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/18547146","citation_count":252,"is_preprint":false},{"pmid":"11431734","id":"PMC_11431734","title":"Expression and role of Bcl-xL in human hepatocellular carcinomas.","date":"2001","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/11431734","citation_count":228,"is_preprint":false},{"pmid":"10979976","id":"PMC_10979976","title":"Bcr/Abl activates transcription of the Bcl-X gene through STAT5.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10979976","citation_count":217,"is_preprint":false},{"pmid":"9437022","id":"PMC_9437022","title":"Bcl-xL is an antiapoptotic regulator for postnatal CNS neurons.","date":"1998","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/9437022","citation_count":214,"is_preprint":false},{"pmid":"7761398","id":"PMC_7761398","title":"Bclx regulates the survival of double-positive thymocytes.","date":"1995","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7761398","citation_count":212,"is_preprint":false},{"pmid":"11085453","id":"PMC_11085453","title":"Regulation of Bcl-xL: a little bit of this and a little bit of STAT.","date":"2000","source":"Current opinion in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/11085453","citation_count":199,"is_preprint":false},{"pmid":"8626425","id":"PMC_8626425","title":"Bcl-x(S) anatagonizes the protective effects of Bcl-x(L).","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8626425","citation_count":187,"is_preprint":false},{"pmid":"19255249","id":"PMC_19255249","title":"Bcl-x L increases mitochondrial fission, fusion, and biomass in neurons.","date":"2009","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19255249","citation_count":184,"is_preprint":false},{"pmid":"9475763","id":"PMC_9475763","title":"Expression of Bcl-x in erythroid precursors from patients with polycythemia vera.","date":"1998","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9475763","citation_count":178,"is_preprint":false},{"pmid":"10545916","id":"PMC_10545916","title":"Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides.","date":"1999","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/10545916","citation_count":171,"is_preprint":false},{"pmid":"7848520","id":"PMC_7848520","title":"Bcl-2 and Bcl-x: regulatory switches for lymphoid death and survival.","date":"1994","source":"Immunology today","url":"https://pubmed.ncbi.nlm.nih.gov/7848520","citation_count":160,"is_preprint":false},{"pmid":"25126723","id":"PMC_25126723","title":"The BCL2L1 and PGAM5 axis defines hypoxia-induced receptor-mediated mitophagy.","date":"2014","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/25126723","citation_count":156,"is_preprint":false},{"pmid":"9885381","id":"PMC_9885381","title":"Immunohistochemical analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 expression in pancreatic cancers.","date":"1999","source":"Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/9885381","citation_count":142,"is_preprint":false},{"pmid":"9226163","id":"PMC_9226163","title":"The roles of Bcl-X(L) and apopain in the control of erythropoiesis by erythropoietin.","date":"1997","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/9226163","citation_count":136,"is_preprint":false},{"pmid":"24813943","id":"PMC_24813943","title":"Mst1 promotes cardiac myocyte apoptosis through phosphorylation and inhibition of Bcl-xL.","date":"2014","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/24813943","citation_count":124,"is_preprint":false},{"pmid":"11332715","id":"PMC_11332715","title":"Transcriptional regulation of the bcl-x gene encoding the anti-apoptotic Bcl-xL protein by Ets, Rel/NFkappaB, STAT and AP1 transcription factor families.","date":"2001","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/11332715","citation_count":116,"is_preprint":false},{"pmid":"19820711","id":"PMC_19820711","title":"Membrane promotes tBID interaction with BCL(XL).","date":"2009","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19820711","citation_count":107,"is_preprint":false},{"pmid":"31552099","id":"PMC_31552099","title":"Modulation of the Apoptosis Gene Bcl-x Function Through Alternative Splicing.","date":"2019","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31552099","citation_count":102,"is_preprint":false},{"pmid":"33664238","id":"PMC_33664238","title":"SRSF1 inhibits autophagy through regulating Bcl-x splicing and interacting with PIK3C3 in lung cancer.","date":"2021","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33664238","citation_count":98,"is_preprint":false},{"pmid":"7542499","id":"PMC_7542499","title":"Primitive human hematopoietic precursors express Bcl-x but not Bcl-2.","date":"1995","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/7542499","citation_count":97,"is_preprint":false},{"pmid":"9516944","id":"PMC_9516944","title":"bcl-2, bax, bcl-XL, and bcl-XS expression in normal and neoplastic ovarian tissues.","date":"1998","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/9516944","citation_count":91,"is_preprint":false},{"pmid":"8695854","id":"PMC_8695854","title":"Bcl-x rather than Bcl-2 mediates CD40-dependent centrocyte survival in the germinal center.","date":"1996","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/8695854","citation_count":86,"is_preprint":false},{"pmid":"9390687","id":"PMC_9390687","title":"A novel Bcl-x isoform connected to the T cell receptor regulates apoptosis in T cells.","date":"1997","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/9390687","citation_count":84,"is_preprint":false},{"pmid":"27537525","id":"PMC_27537525","title":"Bcl-xL is an oncogenic driver in colorectal cancer.","date":"2016","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/27537525","citation_count":83,"is_preprint":false},{"pmid":"8547598","id":"PMC_8547598","title":"Function and expression of the Bcl-x gene in the developing and adult nervous system.","date":"1995","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/8547598","citation_count":83,"is_preprint":false},{"pmid":"19109573","id":"PMC_19109573","title":"Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders.","date":"2008","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19109573","citation_count":79,"is_preprint":false},{"pmid":"31734345","id":"PMC_31734345","title":"Bcl-XL: A multifunctional anti-apoptotic protein.","date":"2019","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/31734345","citation_count":70,"is_preprint":false},{"pmid":"9185996","id":"PMC_9185996","title":"Bcl-x expression influences keratinocyte cell survival but not terminal differentiation.","date":"1997","source":"Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/9185996","citation_count":68,"is_preprint":false},{"pmid":"23533418","id":"PMC_23533418","title":"Functions of BCL-X L at the Interface between Cell Death and Metabolism.","date":"2013","source":"International journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/23533418","citation_count":68,"is_preprint":false},{"pmid":"27572165","id":"PMC_27572165","title":"Eliminating Legionella by inhibiting BCL-XL to induce macrophage apoptosis.","date":"2016","source":"Nature microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/27572165","citation_count":67,"is_preprint":false},{"pmid":"18281479","id":"PMC_18281479","title":"Nucleolin stabilizes Bcl-X L messenger RNA in response to UVA irradiation.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18281479","citation_count":63,"is_preprint":false},{"pmid":"20051518","id":"PMC_20051518","title":"The anti-apoptotic protein BCL2L1/Bcl-xL is neutralized by pro-apoptotic PMAIP1/Noxa in neuroblastoma, thereby determining bortezomib sensitivity independent of prosurvival MCL1 expression.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20051518","citation_count":63,"is_preprint":false},{"pmid":"9366408","id":"PMC_9366408","title":"Bcl-x protects primary B cells against Fas-mediated apoptosis.","date":"1997","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9366408","citation_count":62,"is_preprint":false},{"pmid":"16960143","id":"PMC_16960143","title":"BCL-xL regulates synaptic plasticity.","date":"2006","source":"Molecular interventions","url":"https://pubmed.ncbi.nlm.nih.gov/16960143","citation_count":59,"is_preprint":false},{"pmid":"10777212","id":"PMC_10777212","title":"Bcl-xS and Bax induce different apoptotic pathways in PC12 cells.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10777212","citation_count":59,"is_preprint":false},{"pmid":"31067648","id":"PMC_31067648","title":"The Structural Biology of Bcl-xL.","date":"2019","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31067648","citation_count":58,"is_preprint":false},{"pmid":"32424151","id":"PMC_32424151","title":"BCL-xL/BCL2L1 is a critical anti-apoptotic protein that promotes the survival of differentiating pancreatic cells from human pluripotent stem cells.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/32424151","citation_count":57,"is_preprint":false},{"pmid":"17923691","id":"PMC_17923691","title":"Protein kinase C-dependent control of Bcl-x alternative splicing.","date":"2007","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17923691","citation_count":56,"is_preprint":false},{"pmid":"29156002","id":"PMC_29156002","title":"Specific G-quadruplex ligands modulate the alternative splicing of Bcl-X.","date":"2018","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/29156002","citation_count":55,"is_preprint":false},{"pmid":"11519724","id":"PMC_11519724","title":"Transcriptional regulation of the BCL-X gene by NF-kappaB is an element of hypoxic responses in the rat brain.","date":"2001","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/11519724","citation_count":54,"is_preprint":false},{"pmid":"25731750","id":"PMC_25731750","title":"Conformation of BCL-XL upon Membrane Integration.","date":"2015","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/25731750","citation_count":52,"is_preprint":false},{"pmid":"20192224","id":"PMC_20192224","title":"Fragment-based deconstruction of Bcl-xL inhibitors.","date":"2010","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20192224","citation_count":52,"is_preprint":false},{"pmid":"24992962","id":"PMC_24992962","title":"Long non-coding RNA INXS is a critical mediator of BCL-XS induced apoptosis.","date":"2014","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/24992962","citation_count":49,"is_preprint":false},{"pmid":"26215742","id":"PMC_26215742","title":"Ceramide channels: destabilization by Bcl-xL and role in apoptosis.","date":"2015","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/26215742","citation_count":48,"is_preprint":false},{"pmid":"17699103","id":"PMC_17699103","title":"Modulation of bcl-xL in tumor cells regulates angiogenesis through CXCL8 expression.","date":"2007","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/17699103","citation_count":47,"is_preprint":false},{"pmid":"26401016","id":"PMC_26401016","title":"Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer.","date":"2015","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/26401016","citation_count":46,"is_preprint":false},{"pmid":"34376637","id":"PMC_34376637","title":"BCLXL gene therapy moderates neuropathology in the DBA/2J mouse model of inherited glaucoma.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/34376637","citation_count":45,"is_preprint":false},{"pmid":"29066722","id":"PMC_29066722","title":"BCL-XL directly modulates RAS signalling to favour cancer cell stemness.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29066722","citation_count":44,"is_preprint":false},{"pmid":"31508368","id":"PMC_31508368","title":"Exogenous Let-7a-5p Induces A549 Lung Cancer Cell Death Through BCL2L1-Mediated PI3Kγ Signaling Pathway.","date":"2019","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31508368","citation_count":44,"is_preprint":false},{"pmid":"18494061","id":"PMC_18494061","title":"Significance of Bcl-xL in human colon carcinoma.","date":"2008","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/18494061","citation_count":44,"is_preprint":false},{"pmid":"9444360","id":"PMC_9444360","title":"Bcl-2, Bax and Bcl-x expression following hypoxia-ischemia in the infant rat brain.","date":"1997","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/9444360","citation_count":44,"is_preprint":false},{"pmid":"12721309","id":"PMC_12721309","title":"Regulation of Bcl-xL expression by H2O2 in cardiac myocytes.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12721309","citation_count":43,"is_preprint":false},{"pmid":"16462815","id":"PMC_16462815","title":"Haloperidol induces apoptosis via the sigma2 receptor system and Bcl-XS.","date":"2006","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/16462815","citation_count":42,"is_preprint":false},{"pmid":"15383573","id":"PMC_15383573","title":"bcl-xL is critical for dendritic cell survival in vivo.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15383573","citation_count":42,"is_preprint":false},{"pmid":"34118966","id":"PMC_34118966","title":"Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation.","date":"2021","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/34118966","citation_count":41,"is_preprint":false},{"pmid":"27198225","id":"PMC_27198225","title":"Physiological restraint of Bak by Bcl-xL is essential for cell survival.","date":"2016","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/27198225","citation_count":41,"is_preprint":false},{"pmid":"9502620","id":"PMC_9502620","title":"Bcl-x is a regulatory factor of apoptosis and differentiation in megakaryocytic lineage cells.","date":"1998","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/9502620","citation_count":41,"is_preprint":false},{"pmid":"15846108","id":"PMC_15846108","title":"Enhancing TRAIL-induced apoptosis by Bcl-X(L) siRNA.","date":"2005","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/15846108","citation_count":41,"is_preprint":false},{"pmid":"24787232","id":"PMC_24787232","title":"Bcl-xL is necessary for neurite outgrowth in hippocampal neurons.","date":"2015","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/24787232","citation_count":38,"is_preprint":false},{"pmid":"26254736","id":"PMC_26254736","title":"Propofol-induced rno-miR-665 targets BCL2L1 and influences apoptosis in rodent developing hippocampal astrocytes.","date":"2015","source":"Neurotoxicology","url":"https://pubmed.ncbi.nlm.nih.gov/26254736","citation_count":37,"is_preprint":false},{"pmid":"26416351","id":"PMC_26416351","title":"Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26416351","citation_count":36,"is_preprint":false},{"pmid":"17224645","id":"PMC_17224645","title":"Bcl2/bcl-xL inhibitor engenders apoptosis and increases chemosensitivity in mesothelioma.","date":"2007","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/17224645","citation_count":36,"is_preprint":false},{"pmid":"16081848","id":"PMC_16081848","title":"Spontaneous immunity against Bcl-xL in cancer patients.","date":"2005","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/16081848","citation_count":35,"is_preprint":false},{"pmid":"35086552","id":"PMC_35086552","title":"SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances.","date":"2022","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/35086552","citation_count":34,"is_preprint":false},{"pmid":"25278904","id":"PMC_25278904","title":"Bcl-xL in neuroprotection and plasticity.","date":"2014","source":"Frontiers in physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25278904","citation_count":31,"is_preprint":false},{"pmid":"22836101","id":"PMC_22836101","title":"BCL2L1 (BCL-X) promotes survival of adult and developing retinal ganglion cells.","date":"2012","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/22836101","citation_count":31,"is_preprint":false},{"pmid":"33803452","id":"PMC_33803452","title":"Bcl-xL: A Focus on Melanoma Pathobiology.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33803452","citation_count":29,"is_preprint":false},{"pmid":"35216310","id":"PMC_35216310","title":"Roles and Regulation of BCL-xL in Hematological Malignancies.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35216310","citation_count":29,"is_preprint":false},{"pmid":"9457899","id":"PMC_9457899","title":"Butyrate attenuates BCLX(L) expression in human fibroblasts and acts in synergy with ionizing radiation to induce apoptosis.","date":"1998","source":"Radiation research","url":"https://pubmed.ncbi.nlm.nih.gov/9457899","citation_count":29,"is_preprint":false},{"pmid":"31751869","id":"PMC_31751869","title":"Inhibiting the expression of anti-apoptotic genes BCL2L1 and MCL1, and apoptosis induction in glioblastoma cells by microRNA-342.","date":"2019","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/31751869","citation_count":29,"is_preprint":false},{"pmid":"12569361","id":"PMC_12569361","title":"Bcl-x(L) and Akt cooperate to promote leukemogenesis in vivo.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12569361","citation_count":29,"is_preprint":false},{"pmid":"20680965","id":"PMC_20680965","title":"Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.","date":"2010","source":"Pediatric blood & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/20680965","citation_count":29,"is_preprint":false},{"pmid":"9613974","id":"PMC_9613974","title":"BCL-X and the apoptotic machinery of lymphoma cells.","date":"1998","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/9613974","citation_count":28,"is_preprint":false},{"pmid":"28057797","id":"PMC_28057797","title":"PRMT2 interacts with splicing factors and regulates the alternative splicing of BCL-X.","date":"2017","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28057797","citation_count":28,"is_preprint":false},{"pmid":"33370709","id":"PMC_33370709","title":"Dihydroartemisinin inhibits the tumorigenesis and invasion of gastric cancer by regulating STAT1/KDR/MMP9 and P53/BCL2L1/CASP3/7 pathways.","date":"2020","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/33370709","citation_count":27,"is_preprint":false},{"pmid":"31389670","id":"PMC_31389670","title":"Nonconserved miR-608 suppresses prostate cancer progression through RAC2/PAK4/LIMK1 and BCL2L1/caspase-3 pathways by targeting the 3'-UTRs of RAC2/BCL2L1 and the coding region of PAK4.","date":"2019","source":"Cancer medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31389670","citation_count":26,"is_preprint":false},{"pmid":"11883953","id":"PMC_11883953","title":"Bcl-X(L) and calyculin A prevent translocation of Bax to mitochondria during apoptosis.","date":"2002","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11883953","citation_count":26,"is_preprint":false},{"pmid":"37811881","id":"PMC_37811881","title":"Alternative splicing of BCL-x is controlled by RBM25 binding to a G-quadruplex in BCL-x pre-mRNA.","date":"2023","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/37811881","citation_count":25,"is_preprint":false},{"pmid":"14520471","id":"PMC_14520471","title":"Bcl-x(L) antisense oligonucleotides radiosensitise colon cancer cells.","date":"2003","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/14520471","citation_count":25,"is_preprint":false},{"pmid":"36073545","id":"PMC_36073545","title":"Targeting BCL-XL in fibrolamellar hepatocellular carcinoma.","date":"2022","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/36073545","citation_count":24,"is_preprint":false},{"pmid":"16572289","id":"PMC_16572289","title":"Bcl-x(L) expression in vivo in rheumatoid synovium.","date":"2006","source":"Clinical rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/16572289","citation_count":24,"is_preprint":false},{"pmid":"15110758","id":"PMC_15110758","title":"FAST is a BCL-X(L)-associated mitochondrial protein.","date":"2004","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/15110758","citation_count":24,"is_preprint":false},{"pmid":"12556558","id":"PMC_12556558","title":"Expression of Bcl-x(S) in Xenopus oocytes induces BH3-dependent and caspase-dependent cytochrome c release and apoptosis.","date":"2003","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/12556558","citation_count":24,"is_preprint":false},{"pmid":"9212361","id":"PMC_9212361","title":"Bcl-x and the regulation of survival in the immune system.","date":"1997","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/9212361","citation_count":23,"is_preprint":false},{"pmid":"30809644","id":"PMC_30809644","title":"BMPRII deficiency impairs apoptosis via the BMPRII-ALK1-BclX-mediated pathway in pulmonary arterial hypertension.","date":"2019","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30809644","citation_count":23,"is_preprint":false},{"pmid":"27121046","id":"PMC_27121046","title":"rno-miR-665 targets BCL2L1 (Bcl-xl) and increases vulnerability to propofol in developing astrocytes.","date":"2016","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27121046","citation_count":23,"is_preprint":false},{"pmid":"32788441","id":"PMC_32788441","title":"Oxidative stress battles neuronal Bcl-xL in a fight to the death.","date":"2021","source":"Neural regeneration research","url":"https://pubmed.ncbi.nlm.nih.gov/32788441","citation_count":23,"is_preprint":false},{"pmid":"27579319","id":"PMC_27579319","title":"Modulation of Bcl-x Alternative Splicing Induces Apoptosis of Human Hepatic Stellate Cells.","date":"2016","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/27579319","citation_count":21,"is_preprint":false},{"pmid":"11804960","id":"PMC_11804960","title":"Bcl-x is not required for maintenance of follicles and corpus luteum in the postnatal mouse ovary.","date":"2002","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/11804960","citation_count":21,"is_preprint":false},{"pmid":"12513859","id":"PMC_12513859","title":"Expression of bcl(xs) and c-myc in atretic follicles of mouse ovary.","date":"2001","source":"Reproductive biomedicine online","url":"https://pubmed.ncbi.nlm.nih.gov/12513859","citation_count":20,"is_preprint":false},{"pmid":"18348186","id":"PMC_18348186","title":"Protein phosphatase 1 activation and alternative splicing of Bcl-X and Mcl-1 by EGCG + ibuprofen.","date":"2008","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18348186","citation_count":20,"is_preprint":false},{"pmid":"22537491","id":"PMC_22537491","title":"Zebrafish bcl2l is a survival factor in thyroid development.","date":"2012","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/22537491","citation_count":19,"is_preprint":false},{"pmid":"33982799","id":"PMC_33982799","title":"NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells.","date":"2021","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33982799","citation_count":19,"is_preprint":false},{"pmid":"16723699","id":"PMC_16723699","title":"p21Cip1 protection against hyperoxia requires Bcl-XL and is uncoupled from its ability to suppress growth.","date":"2006","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16723699","citation_count":19,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48000,"output_tokens":7827,"usd":0.130702,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":17229,"output_tokens":5497,"usd":0.111785,"stage2_stop_reason":"end_turn"},"total_usd":0.242487,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"BCL2L1 encodes two alternatively spliced isoforms: Bcl-xL (anti-apoptotic) and Bcl-xS (pro-apoptotic). Bcl-xL stably transfected into an IL-3-dependent cell line inhibits apoptosis upon growth factor withdrawal at least as well as Bcl-2, while Bcl-xS inhibits the protective effect of Bcl-2.\",\n      \"method\": \"Stable transfection of IL-3-dependent cell lines; cell survival assays after growth factor withdrawal; molecular cloning and alternative splicing analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — original discovery paper with functional cellular assays, replicated extensively across the field\",\n      \"pmids\": [\"8358789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Bcl-xL forms stable complexes with Bax both in vitro and in vivo (co-immunoprecipitation), increasing the apoptotic threshold in a dose-dependent manner. Bcl-xS does not form observable heterodimers with other Bcl-2 family members by co-immunoprecipitation from mammalian cells, suggesting it acts by a distinct mechanism rather than by competing for Bax binding.\",\n      \"method\": \"In vitro binding assays; co-immunoprecipitation from mammalian cells; dose-dependent cell survival assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP and in vitro binding with functional dose-response, replicated across labs\",\n      \"pmids\": [\"8626425\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Bcl-xL inserts into synthetic lipid vesicles or planar lipid bilayers and forms pH-sensitive, cation-selective ion-conducting channels with multiple conductance states, similar to pore-forming bacterial toxins.\",\n      \"method\": \"Planar lipid bilayer electrophysiology; synthetic lipid vesicle reconstitution; ion channel recordings\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution in lipid bilayers and vesicles, multiple conductance measurements, consistent with structural data\",\n      \"pmids\": [\"9002522\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The loop domain of Bcl-xL is cleaved by caspases in vitro and in cells undergoing apoptosis. Mutation of the caspase cleavage site combined with a BH1 domain mutation impairs death-inhibitory activity. Once cleaved, the C-terminal fragment of Bcl-xL potently induces apoptosis, converting Bcl-xL from protective to lethal.\",\n      \"method\": \"In vitro caspase cleavage assay; site-directed mutagenesis; cell death assays after Sindbis virus infection or IL-3 withdrawal\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro assay plus mutagenesis plus cellular validation, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"9435230\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Bcr/Abl activates transcription of the BCL-X gene through STAT5. Constitutively active STAT5-1*6 induces Bcl-xL expression and promotes survival. A dominant-negative STAT5 mutant blocks both Bcr/Abl-induced BCL-X promoter activity and Bcl-xL protein increase.\",\n      \"method\": \"Tetracycline-inducible expression system; BCL-X promoter/luciferase reporter assays; dominant-negative STAT5 expression; Western blotting\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter reporter assay with dominant-negative epistasis and protein-level confirmation, single lab, two orthogonal methods\",\n      \"pmids\": [\"10979976\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The RNA-binding protein Sam68 binds BCL-x mRNA and modulates its alternative splicing: Sam68 depletion increases anti-apoptotic Bcl-xL, while its overexpression increases pro-apoptotic Bcl-xS. Tyrosine phosphorylation of Sam68 by Fyn kinase inverts this effect, favoring Bcl-xL splice site selection. Sam68 interacts with hnRNP A1, and hnRNP A1 depletion or mutations impairing this interaction attenuate Bcl-xS splicing.\",\n      \"method\": \"RNA interference; overexpression; co-immunoprecipitation; minigene splicing assays; point mutation analysis of RNA-binding domain\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi knockdown, overexpression, co-IP, and kinase epistasis, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"17371836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PKC inhibition (including staurosporine and more specific PKC inhibitors) shifts BCL-x pre-mRNA splicing toward the pro-apoptotic Bcl-xS isoform. This requires active transcription but no new protein synthesis and is independent of caspase activation. An exonic region upstream of the Bcl-xS 5' splice site mediates the staurosporine-dependent splicing shift when transplanted into other alternative splicing units.\",\n      \"method\": \"PKC inhibitor treatment; minigene splicing assays with deletion and transplant constructs; actinomycin D and caspase inhibitor controls; RT-PCR isoform analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — minigene dissection of cis element plus pharmacological epistasis, single lab\",\n      \"pmids\": [\"17923691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Bcl-xL inhibits mitochondrial outer membrane permeabilization (MOMP) by competing with Bax for activation by tBid. Using full-length recombinant proteins and liposome/mitochondria permeabilization assays, tBid recruits both Bcl-xL and Bax to membranes. Mutagenesis shows both Bcl-xL–tBid and Bcl-xL–Bax interactions contribute to anti-apoptotic function. Bcl-xL sequesters tBid and Bax in nonproductive interactions without forming oligomers, functioning as a dominant-negative Bax.\",\n      \"method\": \"In vitro liposome permeabilization assay; isolated mitochondria MOMP assay; full-length recombinant protein reconstitution; site-directed mutagenesis abolishing specific interactions\",\n      \"journal\": \"PLoS biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution with recombinant proteins, mutagenesis of individual interactions, multiple substrates tested\",\n      \"pmids\": [\"18547146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Membrane strongly promotes binding between tBid and Bcl-xL (truncated at C-terminus). Only the active form tBid (not full-length BID) binds Bcl-xL. A BH3 peptide from BID disrupts the tBid-Bcl-xL complex in solution but only partially in lipid bilayers, indicating that tBid–Bcl-xL interactions in membrane are distinct from those in solution.\",\n      \"method\": \"Fluorescence correlation spectroscopy (FCS) in solution and in lipid bilayers; BH3 peptide competition assay\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — quantitative biophysical reconstitution in defined membrane environments with competition assay, single lab, rigorous controls\",\n      \"pmids\": [\"19820711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Bcl-xL increases the rates of both mitochondrial fission and fusion in neurons, and importantly increases mitochondrial biomass, resulting in longer organelle morphology. These effects are measured in neuronal processes using fluorescence microscopy and computational analysis.\",\n      \"method\": \"Fluorescence microscopy with computational fission/fusion frequency measurement; overexpression of Bcl-xL in cultured neurons\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct quantitative live-imaging with computational analysis, overexpression with defined phenotypic readout, single lab\",\n      \"pmids\": [\"19255249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Bcl-xL retrotranslocates Bax from the mitochondria back into the cytosol in healthy cells. FLIP (fluorescence loss in photobleaching) reveals constant retrotranslocation of wild-type Bax but not intramolecular disulfide-tethered Bax (which is locked in its cytosolic conformation and accumulates on mitochondria). Bcl-xL retrotranslocation activity depends on pro-survival Bcl-2 family proteins.\",\n      \"method\": \"Intramolecular disulfide tethering to constrain Bax conformation; fluorescence loss in photobleaching (FLIP); cell-free MOMP assay; detergent co-immunoprecipitation\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — FLIP live-cell imaging with conformational tethering mutants, cell-free MOMP, and co-IP, rigorous mechanistic dissection\",\n      \"pmids\": [\"21458670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"BCL2L1/Bcl-xL (but not BCL2) suppresses FUNDC1-mediated mitophagy under hypoxia through its BH3 domain. Mechanistically, Bcl-xL interacts with and inhibits the mitochondrial phosphatase PGAM5, preventing dephosphorylation of FUNDC1 at Ser13, which is required for mitophagy activation.\",\n      \"method\": \"Co-immunoprecipitation of Bcl-xL and PGAM5; phosphorylation assays of FUNDC1 Ser13; BCL2 vs BCL2L1 comparison; BH3 domain requirement; mitophagy quantification\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP, phosphorylation state analysis, domain mapping, BCL2 isoform specificity control, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"25126723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Mst1 phosphorylates Bcl-xL at Ser14 within the BH4 domain, antagonizing Bcl-xL–Bax binding. This activates Bax and triggers mitochondria-mediated apoptosis in cardiac myocytes. Mst1 activation is localized to mitochondria via a K-Ras–RASSF1A–Mst1 signaling cassette in response to oxidative stress.\",\n      \"method\": \"In vitro kinase assay; site-directed mutagenesis of Ser14; co-immunoprecipitation of Bcl-xL and Bax; mitochondrial fractionation; cardiac myocyte apoptosis assays\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with mutagenesis, co-IP, subcellular fractionation, and cellular apoptosis readout, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"24813943\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Bcl-xL physically interacts with ceramide via the hydrophobic groove, and this interaction inhibits ceramide channel formation in mitochondrial outer membranes. Bcl-xL point mutations that specifically weaken ceramide binding reduce the ability of Bcl-xL to inhibit ceramide channel formation and protect cells from apoptosis in a stimulus-dependent manner, distinct from but overlapping with Bax channel regulation.\",\n      \"method\": \"Site-directed mutagenesis of Bcl-xL hydrophobic groove; planar lipid membrane ceramide channel assay; fluorescently-labeled ceramide binding; stable expression of mutants in Bcl-xL-deficient cells; apoptosis assays\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — mutagenesis, in vitro channel reconstitution, and in vivo functional rescue, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"26215742\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Bcl-xL conformation upon membrane integration: the C-terminus interacts with a conserved surface groove in the water-soluble state and inserts across the phospholipid bilayer in the membrane-bound state. Contrary to current models, membrane binding does not induce a conformational change in the soluble domain; both states bind a known ligand with affinities modulated by the protein state.\",\n      \"method\": \"NMR spectroscopy of full-length Bcl-xL in detergent-free environments; lipid bilayer reconstitution; ligand binding affinity measurements\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structural analysis with functional ligand binding validation in both soluble and membrane states, single lab\",\n      \"pmids\": [\"25731750\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Physiological restraint of Bak by Bcl-xL is essential for cell survival in vivo. A Bak mutation (E75L in mouse, Q77L in human) specifically disrupts interaction with Bcl-xL without affecting Bak structure or killing activity. Loss of Bcl-xL binding to Bak causes increased apoptotic sensitivity in vitro and significant defects in T-cell and blood platelet survival in vivo.\",\n      \"method\": \"Crystal structure of Bak mutant; surface plasmon resonance binding measurements; mouse genetics (Bak knock-in); T-cell and platelet survival assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — structure-guided mutagenesis with binding quantification plus in vivo genetic model, multiple orthogonal methods\",\n      \"pmids\": [\"27198225\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BCL-xL directly interacts with constitutively active RAS in a BH4 domain-dependent manner. This interaction favors full activation of RAS downstream signaling, leading to RAS-induced expression of stemness regulators and maintenance of cancer initiating cell phenotype, independent of apoptotic pressure.\",\n      \"method\": \"Co-immunoprecipitation of BCL-xL and RAS; BH4 domain mutants; comparative proteomics; functional stemness assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP and domain mutants plus functional assays, single lab, two orthogonal methods\",\n      \"pmids\": [\"29066722\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PRMT2 interacts with the splicing factor SAM68 via its SH3 domain and regulates SAM68 subcellular localization. PRMT2 expression promotes an increase in the BCL-xL/BCL-xS splicing ratio in TNF-α or LPS-stimulated cells, linking PRMT2 to BCL-x alternative splicing regulation.\",\n      \"method\": \"Proteomics (SH3 domain pull-down); co-immunoprecipitation of PRMT2 and SAM68; subcellular localization analysis; RT-PCR splicing isoform quantification\",\n      \"journal\": \"Journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-IP and domain pull-down plus splicing readout, single lab\",\n      \"pmids\": [\"28057797\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"RNA G-quadruplexes (G4s) form in BCL-x pre-mRNA near each of the two alternative 5' splice sites. G4-stabilizing ligands (including ellipticine GQC-05) shift BCL-x splicing, antagonizing the major 5' splice site leading to Bcl-xL and activating the alternative splice site leading to pro-apoptotic Bcl-xS. Ligands act independently at the two splice sites.\",\n      \"method\": \"G4 ligand panel treatment; minigene splicing assays; endogenous splicing RT-PCR; apoptosis assays; structure-activity relationship analysis of G4 ligands\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional ligand panel with structure-activity relationship and minigene validation, single lab\",\n      \"pmids\": [\"29156002\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SRSF1 promotes splicing of the long anti-apoptotic Bcl-xL isoform, which then interacts with Beclin1 to dissociate the Beclin1-PIK3C3 complex, thereby suppressing autophagosome formation. SRSF1 also directly interacts with PIK3C3 to disrupt Beclin1-PIK3C3 interaction.\",\n      \"method\": \"Splicing assays (RT-PCR); co-immunoprecipitation of Bcl-xL and Beclin1; co-immunoprecipitation of SRSF1 and PIK3C3; LC3-II accumulation assays; siRNA knockdown\",\n      \"journal\": \"Signal transduction and targeted therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP of protein complexes plus splicing and autophagy functional readouts, single lab\",\n      \"pmids\": [\"33664238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"RBM25 directly and specifically binds to GQ-2, an RNA G-quadruplex in BCL-x pre-mRNA near the alternative 5' splice site leading to Bcl-xS. This RBM25–rG4 interaction requires the RE (arginine-glutamate-rich) motif of RBM25 and is crucial for Bcl-xS production. G4 ligands (PhenDC3, PhenDH8, PhenDH9) enhance RBM25 binding to GQ-2 rG4, promoting Bcl-xS expression and apoptosis.\",\n      \"method\": \"In vitro RNA pull-down; EMSA; G4 ligand binding assays; RBM25 domain mutagenesis; minigene and endogenous splicing assays; apoptosis assays; G4 ligand screen of 90 compounds\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution of protein-RNA interaction with domain mutagenesis, G4 ligand competition, and functional splicing/apoptosis validation, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"37811881\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"FAST (Fas-activated serine/threonine phosphoprotein) localizes to mitochondria and interacts with BCL-xL at the mitochondrial membrane. The BCL-xL binding domain of FAST maps to a BH3-related domain distinct from the mitochondrial-tethering domain (MTD). Both domains are required for FAST–BCL-xL interaction, but the MTD requirement can be satisfied by a heterologous MTD.\",\n      \"method\": \"Immunofluorescence microscopy; subcellular fractionation; co-immunoprecipitation; domain deletion/transplant experiments\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP with domain mapping and heterologous domain rescue, single lab\",\n      \"pmids\": [\"15110758\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Bcl-xS expressed in Xenopus oocytes localizes predominantly to mitochondria and induces caspase-dependent cytochrome c release that requires the BH3 domain. This apoptotic effect is inhibited by co-expression of Bcl-2 or Bcl-xL. The transmembrane domain and BH3 domain of Bcl-xS are both required for apoptotic effect.\",\n      \"method\": \"Xenopus oocyte expression system; subcellular fractionation; cytochrome c release assay; caspase inhibitor treatment; BH3 and transmembrane domain mutagenesis\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo oocyte expression with domain mutagenesis and mechanistic inhibitor controls, single lab\",\n      \"pmids\": [\"12556558\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Nucleolin binds specifically to AU-rich elements (AUUUA) in the 3'-UTR of BCL-xL mRNA and stabilizes it. Nucleolin overexpression stabilizes BCL-xL mRNA in cells, while nucleolin siRNA knockdown shortens BCL-xL mRNA half-life. The stabilizing effect depends on the poly(A) tail and involves nucleolin–poly(A)-binding protein interaction via RGG motifs.\",\n      \"method\": \"RNA affinity capture with synthetic Bcl-xL 3'-UTR; mass spectrometry identification; RIP (RNA immunoprecipitation); siRNA knockdown; mRNA half-life measurements; overexpression\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA affinity capture with MS identification plus functional mRNA stability assays, single lab\",\n      \"pmids\": [\"18281479\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BMPRII deficiency modulates alternative splicing of BCL-x transcripts in a cell-type-specific manner: promoting Bcl-xL in PASMCs while inhibiting it in endothelial cells. This pro-survival effect is mediated through ALK1 but not ALK3. BMPRII physically interacts with ALK1, and pathogenic mutations in BMPR2 abolish this interaction.\",\n      \"method\": \"Co-immunoprecipitation of BMPRII and ALK1; RT-PCR splicing isoform analysis; cell-type-specific knockdown; apoptosis assays; analysis of PAH patient cells and lungs\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP with pathogenic mutation disruption, splicing analysis in patient-derived cells, single lab\",\n      \"pmids\": [\"30809644\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NOXA upregulation leads to proteasomal degradation of BCL2L1 (Bcl-xL) in daunorubicin-treated AML cells, through the NOX4-ROS-p38 MAPK-GSK3β-CREB signaling axis. Restoration of BCL2L1 expression alleviates daunorubicin-induced mitochondrial depolarization and cell death. NOXA associates with both Bcl-xL and MCL1 by immunoprecipitation.\",\n      \"method\": \"Immunoprecipitation; proteasome inhibitor rescue experiments; siRNA knockdown of pathway components; Western blotting; mitochondrial membrane potential assays\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, proteasomal rescue, pathway inhibitor epistasis, single lab\",\n      \"pmids\": [\"33982799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"BCL-xL is required for dendritic cell survival in vivo. Conditional deletion of bcl-x in skin-residing dendritic cells causes rapid apoptotic disappearance from draining lymph nodes and failure to mount effective immune responses. Trans-complementation with BCL-xL rescues DC survival, and RNAi silencing of the Bcl-xL isoform (but not Bcl-xS) specifically recapitulates the survival defect.\",\n      \"method\": \"Cre-loxP conditional gene deletion in DCs; gene gun DNA vaccine immunization; RNA interference isoform-specific silencing; trans-complementation with Bcl-xL\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional KO with isoform-specific RNAi and complementation rescue, in vivo model with defined cellular phenotype\",\n      \"pmids\": [\"15383573\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Noxa co-immunoprecipitates with endogenous Bcl-xL in neuroblastoma cells (in addition to MCL1), and this association functionally neutralizes Bcl-xL. Retroviral expression of Bcl-xL (but not MCL1) prevents bortezomib-induced apoptosis, and Noxa knockdown reduces cell death, establishing that Noxa-mediated neutralization of Bcl-xL is required for bortezomib-induced apoptosis.\",\n      \"method\": \"Co-immunoprecipitation; shRNA knockdown; retroviral overexpression; apoptosis assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, shRNA epistasis, and isoform-selective rescue, single lab\",\n      \"pmids\": [\"20051518\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Bcl-xL depletion in hippocampal neurons impairs neurite outgrowth followed by delayed cell death dependent on upregulation of death receptor 6 (DR6). DR6 depletion partially rescues neuronal process loss, placing DR6 downstream of Bcl-xL in the regulation of neuronal outgrowth. Under hypoxia, Bcl-xL-depleted neurons show increased DR6, neuronal process loss, and death.\",\n      \"method\": \"shRNA depletion of Bcl-xL and DR6; neurite outgrowth measurement; hypoxia model; epistasis by DR6 rescue of Bcl-xL depletion phenotype\",\n      \"journal\": \"Antioxidants & redox signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — knockdown epistasis with defined neuronal phenotype, single lab\",\n      \"pmids\": [\"24787232\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BCL2L1 produces two antagonistic splice isoforms (Bcl-xL and Bcl-xS) through alternative splicing regulated by multiple RNA-binding proteins (Sam68, RBM25, SRSF1, PRMT2), signaling pathways (PKC, BMPRII-ALK1), and RNA G-quadruplex structures; Bcl-xL, the predominant anti-apoptotic isoform, localizes to mitochondrial, endoplasmic reticulum, and nuclear outer membranes where it inhibits apoptosis by: (1) retrotranslocating Bax from mitochondria to the cytosol, (2) directly binding and restraining Bak via its hydrophobic groove, (3) competing with Bax for membrane recruitment and oligomerization by sequestering tBid and activated Bax, (4) inhibiting ceramide channel formation through its hydrophobic groove, (5) forming a pH-sensitive cation-selective ion channel; Bcl-xL activity is regulated post-translationally by Mst1-mediated phosphorylation at Ser14 (BH4 domain, antagonizing Bax binding) and by caspase cleavage of its loop domain (converting it to a pro-apoptotic fragment); Bcl-xL also suppresses FUNDC1-mediated mitophagy by interacting with and inhibiting PGAM5 phosphatase, promotes autophagy suppression by binding Beclin1 to displace PIK3C3, enhances mitochondrial fission/fusion and biomass in neurons, modulates synaptic plasticity through mitochondrial bioenergetics, and interacts with RAS in a BH4-dependent manner to promote cancer stem cell signaling.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BCL2L1 is a central rheostat of the intrinsic apoptotic pathway whose pre-mRNA is alternatively spliced into the anti-apoptotic Bcl-xL and the pro-apoptotic Bcl-xS isoforms, which functionally oppose one another [#0]. Bcl-xL restrains mitochondrial outer membrane permeabilization through several converging mechanisms: it forms stable heterodimers with Bax to raise the apoptotic threshold [#1], directly binds and physiologically restrains Bak through interactions essential for T-cell and platelet survival in vivo [#15], retrotranslocates Bax from mitochondria back to the cytosol in healthy cells [#10], and competes with Bax for membrane recruitment by sequestering tBid and activated Bax in nonproductive complexes without oligomerizing, acting as a dominant-negative Bax [#7, #8]. Beyond protein–protein restraint, Bcl-xL inserts into membranes to form pH-sensitive, cation-selective ion channels [#2] and binds ceramide via its hydrophobic groove to block ceramide channel formation [#13]; structural work shows its C-terminus toggles between a surface groove in the soluble state and a transmembrane configuration upon membrane integration [#14]. Bcl-xL activity is set post-translationally—Mst1 phosphorylation at Ser14 in the BH4 domain antagonizes Bax binding and licenses apoptosis [#12], while caspase cleavage of its loop domain converts Bcl-xL into a pro-apoptotic fragment [#3]—and is opposed by the BH3-only protein Noxa, which neutralizes Bcl-xL and targets it for proteasomal degradation [#27, #25]. The protective Bcl-xL isoform is essential for survival of dendritic cells [#26] and supports neuronal outgrowth and survival [#28], and it also discharges apoptosis-independent roles: suppressing FUNDC1-mediated mitophagy by inhibiting the PGAM5 phosphatase [#11], suppressing autophagy by binding Beclin1 to displace PIK3C3 [#19], promoting mitochondrial fission/fusion and biomass in neurons [#9], and engaging active RAS through its BH4 domain to sustain cancer stem cell signaling [#16]. The Bcl-xL/Bcl-xS ratio is itself heavily regulated at the RNA level: Sam68 (modulated by Fyn phosphorylation and hnRNP A1) [#5], PKC signaling acting on a cis exonic element [#6], PRMT2 [#17], SRSF1 [#19], and RNA G-quadruplexes near the competing 5' splice sites—read by RBM25 and tunable by G4 ligands—collectively determine isoform choice [#18, #20], while transcription is driven by Bcr/Abl–STAT5 [#4] and mRNA stability by nucleolin binding the 3'-UTR [#23].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Established that a single gene encodes two functionally opposing apoptotic regulators, defining BCL2L1 as a splicing-controlled switch rather than a single anti-apoptotic factor.\",\n      \"evidence\": \"Molecular cloning and stable transfection of IL-3-dependent cells with survival assays after growth factor withdrawal\",\n      \"pmids\": [\"8358789\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which Bcl-xS antagonizes survival not resolved\", \"Splicing regulators unknown at this stage\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Showed Bcl-xL acts in part by direct heterodimerization with Bax, providing a biochemical basis for raising the apoptotic threshold.\",\n      \"evidence\": \"In vitro binding and reciprocal co-IP from mammalian cells with dose-dependent survival assays\",\n      \"pmids\": [\"8626425\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Bax sequestration is the dominant in vivo mechanism unaddressed\", \"Bcl-xS mechanism remained distinct and undefined\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Demonstrated Bcl-xL is itself a membrane pore-former, suggesting a channel activity intrinsic to its function beyond protein binding.\",\n      \"evidence\": \"Planar lipid bilayer electrophysiology and synthetic vesicle reconstitution\",\n      \"pmids\": [\"9002522\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological substrate/ion of the channel in cells not established\", \"Relationship of channel activity to apoptosis control unclear\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Revealed that caspase cleavage converts the protective Bcl-xL into a lethal fragment, establishing a feed-forward proteolytic switch during apoptosis.\",\n      \"evidence\": \"In vitro caspase cleavage, site-directed mutagenesis, and cell death assays\",\n      \"pmids\": [\"9435230\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo contribution of the cleavage fragment to physiological death unquantified\", \"Structural basis of the pro-apoptotic fragment unknown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identified Bcr/Abl–STAT5 as a transcriptional driver of BCL-X, linking oncogenic signaling to Bcl-xL-mediated survival.\",\n      \"evidence\": \"Inducible expression, BCL-X promoter/luciferase reporter, and dominant-negative STAT5 epistasis\",\n      \"pmids\": [\"10979976\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct STAT5 binding to the promoter not mapped\", \"Effect on isoform ratio versus total expression not separated\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined RNA-level control of isoform choice via Sam68 and showed kinase signaling (Fyn, PKC) and a cis exonic element steer splicing toward Bcl-xL or Bcl-xS.\",\n      \"evidence\": \"RNAi, overexpression, co-IP, kinase epistasis, and minigene splicing assays with cis-element transplantation\",\n      \"pmids\": [\"17371836\", \"17923691\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct splice-site mechanism of Sam68/PKC integration unresolved\", \"PKC findings are Medium-confidence single-lab\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Reconstituted MOMP inhibition with recombinant proteins, establishing that Bcl-xL functions as a dominant-negative Bax by sequestering both tBid and activated Bax without oligomerizing.\",\n      \"evidence\": \"In vitro liposome and isolated-mitochondria permeabilization with full-length recombinant proteins and interaction-abolishing mutants\",\n      \"pmids\": [\"18547146\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative weighting of tBid versus Bax sequestration in cells not fixed\", \"Membrane context of these interactions only partly captured\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showed Bcl-xL has apoptosis-independent effects on mitochondrial dynamics, increasing fission, fusion, and biomass in neurons.\",\n      \"evidence\": \"Live fluorescence imaging with computational fission/fusion analysis after Bcl-xL overexpression in neurons\",\n      \"pmids\": [\"19255249\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Overexpression-based; loss-of-function effect on dynamics untested here\", \"Molecular effector linking Bcl-xL to fission/fusion machinery unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Quantified that the membrane environment, not solution conditions, governs tBid–Bcl-xL binding and that only active tBid engages Bcl-xL.\",\n      \"evidence\": \"Fluorescence correlation spectroscopy in solution and lipid bilayers with BH3 peptide competition\",\n      \"pmids\": [\"19820711\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the distinct membrane-bound complex unresolved\", \"Generality to other BH3 ligands not tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established retrotranslocation of Bax from mitochondria to cytosol as a continuous, Bcl-xL-dependent surveillance mechanism in healthy cells.\",\n      \"evidence\": \"FLIP live-cell imaging with conformation-locking Bax disulfide mutants, cell-free MOMP, and co-IP\",\n      \"pmids\": [\"21458670\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Energetics and directionality determinants of retrotranslocation incompletely defined\", \"How signaling tips retrotranslocation toward MOMP not resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Connected post-translational control and non-apoptotic function: Mst1 Ser14 phosphorylation disarms Bcl-xL–Bax restraint, while Bcl-xL inhibits PGAM5 to suppress FUNDC1-mediated mitophagy.\",\n      \"evidence\": \"In vitro kinase assay, Ser14 mutagenesis, co-IP, fractionation, and mitophagy quantification with BCL2 isoform controls\",\n      \"pmids\": [\"24813943\", \"25126723\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo significance of Ser14 phosphorylation outside cardiac myocytes unclear\", \"Structural basis of Bcl-xL–PGAM5 inhibition unmapped\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Expanded Bcl-xL membrane biology: it binds ceramide to block ceramide channels, and structural work defined how its C-terminus repartitions between groove and bilayer without altering the soluble fold.\",\n      \"evidence\": \"Hydrophobic-groove mutagenesis with planar-membrane ceramide channel assays and NMR of full-length protein in soluble and membrane states\",\n      \"pmids\": [\"26215742\", \"25731750\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological frequency of ceramide-channel inhibition versus Bax regulation unquantified\", \"Functional state of the membrane-inserted C-terminus in apoptosis control unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated in vivo that Bcl-xL restraint of Bak (not only Bax) is essential, using a binding-selective Bak mutant that compromises T-cell and platelet survival.\",\n      \"evidence\": \"Crystal structure of Bak mutant, SPR binding, and Bak knock-in mouse genetics with survival assays\",\n      \"pmids\": [\"27198225\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Tissue-specific dependence on Bak versus Bax restraint not fully mapped\", \"Interplay with other pro-survival relatives in vivo unaddressed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Extended Bcl-xL into oncogenic signaling, showing a BH4-dependent interaction with active RAS that sustains stemness independent of apoptotic pressure, and added PRMT2 as a splicing-ratio regulator.\",\n      \"evidence\": \"Co-IP with BH4 domain mutants and stemness assays; PRMT2–SAM68 SH3 pull-down with splicing readout\",\n      \"pmids\": [\"29066722\", \"28057797\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"RAS interaction shown by co-IP without reciprocal structural validation\", \"Direct versus indirect role of PRMT2 on splice-site selection unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified RNA G-quadruplexes near both alternative 5' splice sites as druggable structural determinants of Bcl-xL/Bcl-xS choice.\",\n      \"evidence\": \"G4-ligand panel with minigene and endogenous splicing RT-PCR plus apoptosis assays\",\n      \"pmids\": [\"29156002\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endogenous proteins reading the G4s not identified in this study\", \"Single-lab functional ligand data\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Linked SRSF1-driven Bcl-xL production to autophagy suppression via Beclin1–PIK3C3 dissociation, and showed NOXA-driven proteasomal degradation of Bcl-xL during chemotherapy.\",\n      \"evidence\": \"Splicing RT-PCR with Beclin1/PIK3C3 co-IPs and LC3-II assays; NOXA co-IP with proteasome-inhibitor rescue and pathway epistasis\",\n      \"pmids\": [\"33664238\", \"33982799\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct versus splicing-mediated contribution of SRSF1 to autophagy not fully separated\", \"E3 ligase mediating NOXA-driven degradation not identified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified RBM25 as the direct G-quadruplex reader (via its RE motif) that promotes Bcl-xS production, providing a protein basis for G4-ligand-tunable splicing.\",\n      \"evidence\": \"In vitro RNA pull-down, EMSA, RBM25 domain mutagenesis, G4-ligand competition, and splicing/apoptosis assays\",\n      \"pmids\": [\"37811881\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Interplay of RBM25 with other splicing factors at the locus unresolved\", \"Structural model of the RBM25–rG4 complex not determined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the many layers of regulation—transcription, mRNA stability, splice-isoform choice, post-translational modification, and degradation—are integrated to set the Bcl-xL/Bcl-xS balance in a given cell context remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified quantitative model linking splicing regulators to apoptotic outcome\", \"Context-specific weighting of apoptotic versus non-apoptotic Bcl-xL functions unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [7, 10, 1, 15]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [11, 12]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [13]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005741\", \"supporting_discovery_ids\": [10, 11, 12, 21]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [9, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 1, 7, 10, 15]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [11, 19]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [5, 18, 20]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"BAX\", \"BAK1\", \"BID\", \"PGAM5\", \"BECN1\", \"PMAIP1\", \"HRAS\", \"SAM68\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}